Next 10 |
2024-07-19 14:40:20 ET More on HSBC Holdings, Otis Worldwide HSBC: Q2 2024 Earnings Preview, Investment Case Remains Geared To Income Otis Worldwide: Solid Fundamentals And Growth Levers, But Highly Valued, Hold HSBC: Limited Upside Potential With Some Headwinds (Rat...
2024-07-17 06:39:26 ET More on ChromaDex ChromaDex: Looking To Take The Big Step Into Pharma Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Read the full article on Seeking Alpha For further details see: Ch...
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
2024-07-01 08:39:20 ET More on ChromaDex ChromaDex: Looking To Take The Big Step Into Pharma ChromaDex Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Read the full article on Seeking ...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
2024-06-26 12:20:23 ET Summary ChromaDex Corporation is a leader in NAD+ development for healthy aging with Tru Niagen, showing strong growth and attractive valuation. ChromaDex is making a move into the pharma industry with NRC candidate for AT, receiving FDA designations and pre...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...
Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized nicotinamide riboside...
2024-06-07 09:51:21 ET More on BioCardia, ChromaDex, etc. Charles River Laboratories: Fair Valuation Against Fundamentals BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss' BioCardia inte...
ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, ...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...